Isoniazid in patient plasma may cause a false-positive result on the complement-dependent cytotoxicity test

Francesca Poli, Annalisa Innocente, Nicoletta Cagni, Caterina Brambilla, Loretta Crespiatico, Maria Bernadette Colombo, Mario Scalamogna

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Correct definition of clinically relevant anti-HLA antibodies is important for transplant organ allocation and outcome. We describe a candidate for kidney transplantation who was treated with isoniazid because of active tuberculosis. The patient's serum gave a positive antibody result on screening with the complement-dependent cytotoxicity (CDC) test but a negative result on screening with a bead-based assay (Luminex). The clinical history indicated no immunologic stimuli. Subsequent testing on fresh serum samples confirmed the discrepancy between CDC and Luminex results. An autologous cross-match test gave negative results, and the antibodies were sensitive to dithiothreitol treatment. We postulated that nonspecific binding of drug-antibody complexes to panel lymphocytes in the CDC test may have caused the observed lympholysis. This case, although isolated, emphasizes the importance of the combined use of CDC and solid phase assays. The CDC results alone would have led to the erroneous conclusion that the patient was highly sensitized.

Original languageEnglish
Pages (from-to)758-759
Number of pages2
JournalHuman Immunology
Volume70
Issue number9
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Isoniazid
Antibodies
Dithiothreitol
Serum
Kidney Transplantation
Anti-Idiotypic Antibodies
Tuberculosis
Lymphocytes
Transplants
Pharmaceutical Preparations
Therapeutics

Keywords

  • Anti-HLA antibodies
  • Isoniazid
  • Lymphocytotoxicity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Poli, F., Innocente, A., Cagni, N., Brambilla, C., Crespiatico, L., Colombo, M. B., & Scalamogna, M. (2009). Isoniazid in patient plasma may cause a false-positive result on the complement-dependent cytotoxicity test. Human Immunology, 70(9), 758-759. https://doi.org/10.1016/j.humimm.2009.06.012

Isoniazid in patient plasma may cause a false-positive result on the complement-dependent cytotoxicity test. / Poli, Francesca; Innocente, Annalisa; Cagni, Nicoletta; Brambilla, Caterina; Crespiatico, Loretta; Colombo, Maria Bernadette; Scalamogna, Mario.

In: Human Immunology, Vol. 70, No. 9, 09.2009, p. 758-759.

Research output: Contribution to journalArticle

Poli, F, Innocente, A, Cagni, N, Brambilla, C, Crespiatico, L, Colombo, MB & Scalamogna, M 2009, 'Isoniazid in patient plasma may cause a false-positive result on the complement-dependent cytotoxicity test', Human Immunology, vol. 70, no. 9, pp. 758-759. https://doi.org/10.1016/j.humimm.2009.06.012
Poli, Francesca ; Innocente, Annalisa ; Cagni, Nicoletta ; Brambilla, Caterina ; Crespiatico, Loretta ; Colombo, Maria Bernadette ; Scalamogna, Mario. / Isoniazid in patient plasma may cause a false-positive result on the complement-dependent cytotoxicity test. In: Human Immunology. 2009 ; Vol. 70, No. 9. pp. 758-759.
@article{debbda3bb0a54231b1baaaad888fc1a9,
title = "Isoniazid in patient plasma may cause a false-positive result on the complement-dependent cytotoxicity test",
abstract = "Correct definition of clinically relevant anti-HLA antibodies is important for transplant organ allocation and outcome. We describe a candidate for kidney transplantation who was treated with isoniazid because of active tuberculosis. The patient's serum gave a positive antibody result on screening with the complement-dependent cytotoxicity (CDC) test but a negative result on screening with a bead-based assay (Luminex). The clinical history indicated no immunologic stimuli. Subsequent testing on fresh serum samples confirmed the discrepancy between CDC and Luminex results. An autologous cross-match test gave negative results, and the antibodies were sensitive to dithiothreitol treatment. We postulated that nonspecific binding of drug-antibody complexes to panel lymphocytes in the CDC test may have caused the observed lympholysis. This case, although isolated, emphasizes the importance of the combined use of CDC and solid phase assays. The CDC results alone would have led to the erroneous conclusion that the patient was highly sensitized.",
keywords = "Anti-HLA antibodies, Isoniazid, Lymphocytotoxicity",
author = "Francesca Poli and Annalisa Innocente and Nicoletta Cagni and Caterina Brambilla and Loretta Crespiatico and Colombo, {Maria Bernadette} and Mario Scalamogna",
year = "2009",
month = "9",
doi = "10.1016/j.humimm.2009.06.012",
language = "English",
volume = "70",
pages = "758--759",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Isoniazid in patient plasma may cause a false-positive result on the complement-dependent cytotoxicity test

AU - Poli, Francesca

AU - Innocente, Annalisa

AU - Cagni, Nicoletta

AU - Brambilla, Caterina

AU - Crespiatico, Loretta

AU - Colombo, Maria Bernadette

AU - Scalamogna, Mario

PY - 2009/9

Y1 - 2009/9

N2 - Correct definition of clinically relevant anti-HLA antibodies is important for transplant organ allocation and outcome. We describe a candidate for kidney transplantation who was treated with isoniazid because of active tuberculosis. The patient's serum gave a positive antibody result on screening with the complement-dependent cytotoxicity (CDC) test but a negative result on screening with a bead-based assay (Luminex). The clinical history indicated no immunologic stimuli. Subsequent testing on fresh serum samples confirmed the discrepancy between CDC and Luminex results. An autologous cross-match test gave negative results, and the antibodies were sensitive to dithiothreitol treatment. We postulated that nonspecific binding of drug-antibody complexes to panel lymphocytes in the CDC test may have caused the observed lympholysis. This case, although isolated, emphasizes the importance of the combined use of CDC and solid phase assays. The CDC results alone would have led to the erroneous conclusion that the patient was highly sensitized.

AB - Correct definition of clinically relevant anti-HLA antibodies is important for transplant organ allocation and outcome. We describe a candidate for kidney transplantation who was treated with isoniazid because of active tuberculosis. The patient's serum gave a positive antibody result on screening with the complement-dependent cytotoxicity (CDC) test but a negative result on screening with a bead-based assay (Luminex). The clinical history indicated no immunologic stimuli. Subsequent testing on fresh serum samples confirmed the discrepancy between CDC and Luminex results. An autologous cross-match test gave negative results, and the antibodies were sensitive to dithiothreitol treatment. We postulated that nonspecific binding of drug-antibody complexes to panel lymphocytes in the CDC test may have caused the observed lympholysis. This case, although isolated, emphasizes the importance of the combined use of CDC and solid phase assays. The CDC results alone would have led to the erroneous conclusion that the patient was highly sensitized.

KW - Anti-HLA antibodies

KW - Isoniazid

KW - Lymphocytotoxicity

UR - http://www.scopus.com/inward/record.url?scp=68949177115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949177115&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2009.06.012

DO - 10.1016/j.humimm.2009.06.012

M3 - Article

VL - 70

SP - 758

EP - 759

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 9

ER -